Lawmakers and Advocates Accelerate Push for Federal Cannabis Reform in Washington

Momentum for federal cannabis reform is building on Capitol Hill as a bipartisan group of lawmakers recently underscored the urgent need for legislative action. At a high-profile event, Rep. Ilhan Omar (D-MN) captured the growing impatience among voters and policymakers, declaring, “it’s about damn time Congress caught up” with public opinion on marijuana legalization. Rep. Steve Cohen (D-TN) illustrated the scale of institutional hurdles, likening Drug Enforcement Administration barriers to “the Strait of Hormuz for marijuana legislation.” Their remarks reflect a broader frustration with the slow pace of federal change despite significant shifts at state and international levels

Beyond cannabis, lawmakers are also turning their attention to psychedelics and alternative therapies. Rep. Lou Correa (D-CA) described psychedelic treatments as a potential “magic cure” for mental health conditions, signaling growing bipartisan interest in expanding access for vulnerable populations. Rep. Jack Bergman (R-MI) emphasized the moral imperative to support military veterans and others, stating that providing access to these therapies is “the right thing for Congress to do.” These statements highlight a widening policy conversation that now encompasses both cannabis and psychedelics as viable options for medical and therapeutic use

Internationally, significant developments are also underway. The Colombian House of Representatives First Committee approved a bill to legalize marijuana, with its sponsor emphasizing the bill's potential to “help homeless people, help farmers and indigenous and Afro-Colombian communities who have lived with this plant for many years.” This move positions Colombia as a potential leader in Latin American cannabis reform and signals a recognition of the plant’s historical and cultural significance in the region. Meanwhile, the Philippine Senate experienced dramatic scenes as gunfire erupted during proceedings related to the nation's controversial 'war on drugs,' underscoring the high stakes of drug policy debates globally

At the state level, the pace of reform continues to accelerate. Louisiana lawmakers introduced a measure to establish a Recreational Cannabis Policy Task Force tasked with studying legalization and providing recommendations on taxation, licensing, health, criminal justice, and equity. In Maryland, Governor Wes Moore signed legislation expanding regulatory oversight of substances like kratom, while Colorado issued health advisories on cannabis products with unsafe levels of contaminants. Notably, Maine and New York regulators provided updates on legislative changes and industry growth, and Minnesota saw the opening of its first cannabis consumption lounge, reflecting the diversity of state-level experimentation

Economic and health studies are further shaping the cannabis policy landscape. Research revealed that Nevada could be missing out on $80 million in annual marijuana tax revenue due to regulations separating cannabis and gaming industries. Another study suggested that “medical cannabis may be a useful adjunct therapy for reducing opioid use, relieving chronic pain, and improving health-related quality of life.” On the business front, Michigan retailers reported $258.6 million in legal marijuana sales for April, while major cannabis companies released quarterly financial results amid ongoing regulatory and labor challenges

From the OG Lab newsroom perspective, this wave of legislative and regulatory activity demonstrates how cannabis reform is no longer confined to the margins of American politics. As federal lawmakers, state officials, and international partners advance new policies and research, the cannabis industry finds itself at a critical juncture. This rapid evolution is worth watching closely, as it could reshape not only U.S. drug policy but also influence global standards and market opportunities in the years ahead